检索结果-南通市图书馆

Microvessel density at different levels of normal or injured bile duct in dogs and its surgical implications

hepatobiliary & Pancreatic Diseases International 2011年第1期10卷 83-87页

作者： lin geng,ding luo,hao-chun zhang,liang-song zhao and de-ke qing department of hepatobiliary surgery,kunming general hospital of pla,kunming 650032,china department of hepatobiliary surgery Kunming General Hospital of PLA Kunming 650032 China

BACKGROUND:Ischemic recurrent stricture after surgical repair for iatrogenic bile duct injury(BDI)remains a challenge in clinical *** present study was designed to investigate whether ischemia is universal and of varied severity at different levels of the proximal bile duct after BDI. METHODS:A total of 30 beagle dogs were randomly divided into control,BDI,and BDI-repaired *** BDI animal model was established based on the classic pattern of laparoscopic cholecystectomy-related *** animals were sacrificed on postoperative day 15,and bile duct tissue was harvested to assess microvessel density(MVD)at selected levels of the normal,post-BDI and BDI-repaired bile duct with the CD34 immunohistochemistry technique. RESULTS:In the control group,MVD at level H(high level) was remarkably higher than that at level L(low level).No significant difference was found between MVDs at levels H and M(middle level),as well as at levels M and ***, the tendency was noted that the closer the level to the hilus, the greater the MVD at that *** both the BDI and BDI-repaired groups,MVDs at level H were generally greater than those at level L,despite the unremarkable differences between MVDs at neighboring *** these two groups,a similar tendency of MVD distribution to that in the control group was found;the closer the level to the injury site,the lower was the MVD at that ***,compared with the MDVs at the levels M and L in the control group,MVDs at the corresponding levels in the BDI and BDI-repaired groups were all remarkably reduced(Pdeclined further after BDI ***:After BDI,universal ischemic damage in the injured proximal bile duct develops close to the injury site, while close to the hilus,ischemia is relatively *** hepaticojejunostomy,rather than low biloenterostomy or end-to-end duct anastomosis,should be recommended for BDI *** care

关键词： microvessel density bile duct injury laparoscopic cholecystectomy ischemia reconstruction

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Consensus statement on research and application of Chinese herbal medicine derived extracellular vesicles-like particles(2023 edition)

引用

Chinese Herbal Medicines 2024年第1期16卷 3-12页

作者： qing zhao Tong Wang Hongbin Wang Peng Cao Chengyu Jiang Hongzhi Qiao Lihua Peng Xingdong lin Yunyao Jiang Honglei Jin Huantian zhang Shengpeng Wang Yang Wang Ying Wang Xi Chen Junbing Fan Bo Li geng Li Bifeng Liu Zhiyang Li Suhua Qi Mingzhen zhang Jianjian Zheng Jiuyao Zhou Lei Zheng kewei zhao Guangdong Engineering Research Center of Chinese Herbal Vesicles The Third Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510378China Guangzhou key Laboratory of Chinese Medicine Research on Prevention and Treatment of Osteoporosis The Third Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510378China Institute of Life and Health Engineering the First Affiliated HospitalJinan UniversityGuangzhou 510630China School of Pharmaceutical Sciences Guangzhou University of Chinese MedicineGuangzhou 510006China College of Pharmacy Nanjing University of Chinese MedicineNanjing 210046China Institute of Basic Medicine Chinese Academy of Medical SciencesBeijing 100005China College of Pharmaceutical Sciences Zhejiang UniversityHangzhou 310030China School of Pharmaceutical Sciences Tsinghua UniversityBeijing 100084China department of Bone and Joint surgery The First Affiliated Hospital of Jinan UniversityGuangzhou 510630China State key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical SciencesUniversity of MacaoAomen 999078China Shanghai Jiao Tong University Affiliated Sixth People’s hospital Shanghai 200233China School of Basic Medical Sciences Southern Medical UniversityGuangzhou 510515China School of Life Sciences Nanjing UniversityNanjing 210008China Nanfang hospital Southern Medical UniversityGuangzhou 510515China Laboratory Animal Center Guangzhou University of Chinese MedicineGuangzhou 510405China College of Life Science and Technology Huazhong University of Science and TechnologyWuhan 430074China Nanjing University Medical School Affiliated Nanjing Drum Tower hospital Nanjing 210008China School of Medical and Technology Xuzhou Medical UniversityXuzhou 221004China School of Basic Medical Sciences Xi’an Jiaotong UniversityXi’an 710065China The First Affiliated hospital of Wenzhou Medical University WenZhou 325035China

To promote the development of extracellular vesicles of herbal medicine especially the establishment of standardization,led by the National Expert Committee on Research and Application of Chinese Herbal Vesicles,research experts in the field of herbal medicine and extracellular vesicles were invited nationwide with the support of the Expert Committee on Research and Application of Chinese Herbal Vesicles,Professional Committee on Extracellular Vesicle Research and Application,Chinese Society of Research hospitals and the Guangdong Engineering Research Center of Chinese Herbal *** on the collation of relevant literature,we have adopted the delphi method,the consensus meeting method combined with the nominal group method to form a discussion draft of“Consensus statement on research and application of Chinese herbal medicine derived extracellular vesicles-like particles(2023)”.The first draft was discussed in online and offline meetings on October 12,14,November 2,2022 and April and May 2023 on the current status of research,nomenclature,isolation methods,quality standards and research applications of extracellular vesicles of Chinese herbal medicines,and 13 consensus opinions were finally *** the Third Academic Conference on Research and Application of Chinese Herbal Vesicles,held on May 26,2023,kewei zhao,convenor of the consensus,presented and read the consensus to the experts of the Expert Committee on Research and Application of Chinese Herbal *** consensus highlights the characteristics and advantages of Chinese medicine,inherits the essence,and keeps the righteousness and innovation,aiming to provide a reference for colleagues engaged in research and application of Chinese herbal vesicles at home and abroad,decode the mystery behind Chinese herbal vesicles together,establish a safe,effective and controllable accurate Chinese herbal vesicle prevention and treatment system,and build a bridge for Chinese medicine to the world.

关键词： Chinese herbal medicine extracellular vesicles research application consensus

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Real-world Effectiveness and Tolerability of Interferonfree Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C:A Multinational Cohort Study

引用

Journal of Clinical and Translational Hepatology 2024年第7期12卷 646-658页

作者： Fanpu Ji Sally Tran Eiichi Ogawa chung-Feng Huang Takanori Suzuki Yu Jun Wong Hidenori Toyoda Dae Won Jun Liu Li Haruki Uojima Akito Nozaki Makoto Chuma Cheng-hao Tseng Yao-chun Hsu Masatoshi Ishigami Takashi Honda Masanori Atsukawa Hiroaki Haga Masaru Enomoto Huy Trinh Carmen Monica Preda Phillip Vutien Charles Landis Dong Hyun Lee Tsunamasa Watanabe Hirokazu Takahashi Hiroshi Abe Akira Asai Yuichiro Eguchi Jie Li Xiaozhong Wang Jia Li Junping Liu Jing liang Carla Pui-Mei Lam Rui Huang qing Ye Hongying Pan Jiajie zhang Dachuan Cai Qi Wang Daniel Q.Huang Grace Wong Vincent Wai-Sun Wong Junyi Li Son Do Norihiro Furusyo Makoto Nakamuta Hideyuki Nomura Eiji Kajiwara Eileen L.Yoon Sang Bong Ahn Koichi Azuma Kazufumi Dohmen Jihyun An Do Seon song Hyun Chin Cho Akira Kawano Toshimasa Koyanagi Aritsune Ooho Takeaki Satoh Kazuhiro Takahashi Ming-Lun Yeh Pei-Chien Tsai Satoshi Yasuda Yunyu zhao Yishan Liu Tomomi Okubo Norio Itokawa Mi Jung Jun Toru Ishikawa Koichi Takaguchi Tomonori Senoh Mingyuan zhang Changqing zhao Raluca Ioana Alecu Wei Xuan Tay Pooja devan Joanne Kimiko Liu Ritsuzo Kozuka Elena Vargas-Accarino Ai-Thien Do Mayumi Maeda Wan-Long Chuang Jee-Fu Huang Chia-Yen Dai Ramsey Cheung Maria Buti Junqi Niu Wen Xie Hong Ren Seng Gee Lim Chao Wu Man-Fung Yuen Jia Shang Qiang Zhu Yoshiyuki Ueno Yasuhito Tanaka Jun Hayashi Ming-Lung Yu Mindie H.Nguyen department of Infectious Diseases The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxiChina Division of Gastroenterology and Hepatology Department of MedicineStanford University Medical CenterPalo AltoCAUSA department of general Internal Medicine Kyushu University HospitalFukuokaJapan hepatobiliary Division Department of Internal MedicineKaohsiung Medical University HospitalKaohsiung Hepatitis Research Center College of Medicine and Center for Liquid Biopsy and Cohort ResearchKaohsiung Medical UniversityKaohsiung department of Gastroenterology and Metabolism Nagoya City University Graduate School of Medical SciencesNagoyaJapan Gastroenterology&Hepatology Changi General HospitalSinghealthSingapore Singhealth Duke-NUS Medicine Academic Clinical Program Singapore department of Gastroenterology Ogaki Municipal HospitalOgakiJapan department of Internal Medicine Hanyang UniversityCollege of MedicineSeoulKorea Hanyang Institute of Bioscience and Biotechnology Hanyang UniversitySeoulKorea department of Hepatology The Third People's Hospital of Kunming CityKunmingYunnanChina department of Gastroenterology Internal MedicineKitasato University School of MedicineSagamiharaJapan Gastroenterological Center Yokohama City University Medical CenterYokohamaJapan Division of Gastroenterology and Hepatology Department of Internal MedicineE-Da Cancer HospitalKaohsiung department of Gastroenterology and Hepatology Nagoya University Graduate School of MedicineNagoyaJapan Division of Gastroenterology and Hepatology Nippon Medical SchoolTokyoJapan department of Gastroenterology Yamagata University Faculty of MedicineYamagataJapan department of Transfusion Medicine and department of Hepatology Osaka Metropolitan University Graduate School of MedicineOsakaJapan San Jose Gastroenterology San JoseCAUSA Gastroenterology&Hepatology department Clinic Fundeni InstituteBucharestRomania Division of Gastroenterology and Hepatology University of WashingtonSeattleWAUSA department of

Background and Aims:As practice patterns and hepatitis C virus(HCV)genotypes(GT)vary geographically,a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination *** study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with all HCV GTs,focusing on GT3 and ***:We analyzed the sustained virological response(SVR12)of 15,849 chronic hepatitis C patients from 39 Real-World Evidence from the Asia Liver Consortium for HCV clinical sites in Asia Pacific,North America,and Europe between 07/01/2014–07/01/***:The mean age was 62±13 years,with 49.6%*** demographic breakdown was 91.1%Asian(52.9%Japanese,25.7%Chinese/Taiwan residents,5.4%Korean,3.3%Malaysian,and 2.9%Vietnamese),6.4%White,1.3%Hispanic/Latino,and 1%Black/***,34.8%had cirrhosis,8.6%had hepatocellular carcinoma(HCC),and 24.9%were treatment-experienced(20.7%with interferon,4.3%with direct-acting antivirals).The largest group was GT1(10,246[64.6%]),followed by GT2(3,686[23.2%]),GT3(1,151[7.2%]),GT6(457[2.8%]),GT4(47[0.3%]),GT5(1[0.006%]),and untyped GTs(261[1.6%]).The overall SVR12 was 96.9%,with rates over 95%for GT1/2/3/6 but 91.5%for ***12 for GT3 was 95.1%overall,98.2%for GT3a,and 94.0%for ***12 was 98.3%overall for GT6,lower for patients with cirrhosis and treatment-experienced(TE)(93.8%)but≥97.5%for tretment-naive patients regardless of cirrhosis *** multivariable analysis,advanced age,prior treatment failure,cirrhosis,active HCC,and GT3/4 were independent predictors of lower SVR12,while being Asian was a significant predictor of achieving ***:In this diverse multinational realworld cohort of patients with various GTs,the overall cure rate was 96.9%,despite large numbers of patients with cirrhosis,HCC,TE,and GT3/***12 for GT3/6 with cirrhosis and TE was lower but st

关键词： Hepatitis C virus Liver cirrhosis Hepatocellular carcinoma Genotype DAA REAL-C

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Estimating survival benefit of adjuvant therapy based on a Bayesian network prediction model in curatively resected advanced gallbladder adenocarcinoma

引用

World Journal of Gastroenterology 2019年第37期25卷 5655-5666页

作者： Zhi-Min geng Zhi-Qiang Cai Zhen zhang zhao-Hui Tang Feng Xue Chen Chen Dong zhang Qi Li Rui zhang Wen-Zhi Li lin Wang Shu-Bin Si department of hepatobiliary surgery The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061Shaanxi ProvinceChina department of Industrial Engineering School of Mechanical EngineeringNorthwestern Polytechnical UniversityXi’an 710072Shaanxi ProvinceChina department of general surgery Shanghai Xin Hua Hospital Affiliated to School of MedicineShanghai Jiaotong UniversityShanghai 200092China

BACKGROUND The factors affecting the prognosis and role of adjuvant therapy in advanced gallbladder carcinoma(GBC)after curative resection remain *** To provide a survival prediction model to patients with GBC as well as to identify the role of adjuvant *** Patients with curatively resected advanced gallbladder adenocarcinoma(T3 and T4)were selected from the Surveillance,Epidemiology,and End Results database between 2004 and 2015.A survival prediction model based on Bayesian network(BN)was constructed using the tree-augmented na?ve Bayes algorithm,and composite importance measures were applied to rank the influence of factors on *** dataset was divided into a training dataset to establish the BN model and a testing dataset to test the model randomly at a ratio of 7:*** confusion matrix and receiver operating characteristic curve were used to evaluate the model *** A total of 818 patients met the inclusion *** median survival time was 9.0 *** accuracy of BN model was 69.67%,and the area under the curve value for the testing dataset was 77.72%.Adjuvant radiation,adjuvant chemotherapy(CTx),T stage,scope of regional lymph node surgery,and radiation sequence were ranked as the top five prognostic factors.A survival prediction table was established based on T stage,N stage,adjuvant radiotherapy(XRT),and *** distribution of the survival time(>9.0 mo)was affected by different treatments with the order of adjuvant chemoradiotherapy(cXRT)>adjuvant radiation>adjuvant chemotherapy>surgery *** patients with node-positive disease,the larger benefit predicted by the model is adjuvant *** survival analysis showed that there was a significant difference among the different adjuvant therapy groups(log rank,surgery alone vs CTx,Psurgery alone vs XRT,P=0.014;surgery alone vs cXRT,Pdel can be used as a decision-making support tool for advanced

关键词： Gallbladder carcinoma Bayesian network surgery Adjuvant therapy Prediction model

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi deng Wei Li Ya-ni He zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng Liu Li-hua Wang Rong Wang Nian-song Wang Xiao-hong Cheng Li-qun He Ping luo Shi-ren Sun Ji-feng Sun Ai-ping Yin geng-ru Jiang Hong-yu Chen Wen-hu Liu Hong-li lin Meng liang Lu Ma Ming Chen Li-qun song Jian Chen qing Zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li Ying Li hao zhang Ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China department of Nephrology Tianjin Medical University General HospitalTianjin 300052China department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in china and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

引用

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-liang Li Ming-Sheng Huang Wei-Zhu Yang Guo-Wen Yin Bin-Yan Zhong Jun-Hui Sun Zhi-Cheng Jin Jian-Jian Chen Nai-Jian Ge Wen-Bin ding Wen-Hui Li Jin-Hua Huang Wei Mu Shan-Zhi Gu Jia-Ping Li Hui zhao Shu-Wei Wen Yan-Ming Lei Yu-Sheng song chun-Wang Yuan Wei-Dong Wang Ming Huang Wei zhao Jian-Bing Wu song Wang Xu Zhu Jian-Jun Han Wei-Xin Ren Zai-Ming Lu Wen-Ge Xing Yong Fan Hai-Lan lin Zi-Shu zhang Guo-Hui Xu Wen-hao Hu Qiang Tu Hong-Ying Su Chuan-Sheng Zheng Yong Chen Xu-Ya zhao Zhu-Ting Fang Qi Wang Jin-Wei zhao Ai-Bing Xu Jian Xu qing-Hua Wu Huan-zhang Niu Jian Wang Feng Dai Dui-Ping Feng qing-Dong Li Rong-Shu Shi Jia-Rui Li Guang Yang Hai-Bin Shi Jian-song Ji Yu-E Liu Zheng Cai Po Yang Yang zhao Xiao-Li Zhu Li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China department of Interventional Radiology Nantong First People’s HospitalNantong 226001China department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China department of Vascular surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Pde 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis

引用

Journal of Clinical and Translational Hepatology 2020年第3期8卷 255-261页

作者： Huiying Rao Xingxiang Yang Youwen Tan Qin Ning Daokun Yang Jiefei Wang Yongfeng Yang Sujun Zheng Dongliang Yang Jinlin Hou qing Xie Caiyan zhao Lunli zhang Xiaorong Mao Tong Sun Lang Bai Fuchun zhang Jinglan Jin Yingren zhao Maorong Wang Wen Xie Yingjie Ma Jun Quan Xuebing Yan Ping An Feng lin Jidong Jia Xiaoxuan Hu Zuojiong Gong Jie Wu Yongping Chen Zhansheng Jia Minghua lin Guiqiang Wang Yueyong Zhu Yingjun zhang Hongming Xie lin luo qingyun Ren Rui Huang Lai Wei Peking University People’s hospital Peking University Hepatology InstituteNational Clinical Research Center for Infectious DiseaseBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver DiseasesBeijing International Cooperation Base for Science and Technology on NAFLD DiagnosisBeijingChina department of Infectious Diseases Sichuan Provincial People’s HospitalChengduSichuanChina department of Hepatology The Third People’s Hospital of ZhenjiangZhenjiangJiangsuChina department of Infectious Diseases Tongji HospitalTongji Medical College Huazhong University of Science and TechnologyWuhanHubeiChina department of Infectious Diseases The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenanChina Shanghai Public Health Clinical Center ShanghaiChina department of Hepatology The Second Hospital of NanjingNanjingJiangsuChina Center of Artificial liver Beijing Youan HospitalCapital Medical UniversityBeijingChina department of Infectious Disease Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina department of Infectious Diseases Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongChina department of Infectious Diseases Ruijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghaiChina department of Infectious Diseases The Third Hospital of Hebei Medical UniversityShijiazhuangHebeiChina department of Infectious Diseases The First Affiliated Hospital of Nanchang UniversityNanchangJiangxiChina department of Infectious Diseases The First Hospital of Lanzhou UniversityLanzhouGansuChina department of Infectious Diseases Wuxi Fifth People’s HospitalWuxiJiangsuChina Infectious Diseases Center West China HospitalSichuan UniversityChengduSichuanChina department of Hepatology Guangzhou Eighth People’s HospitalGuangzhouGuangdongChina department of Hepato-Biliary-Pancreatic Diseases The First Hospital of Jilin UniversityChangchunJilinChina department of Infectious Diseases Xi’an Ji

Publications>Journals>Journal of Clinical and Translational Hepatology>Article Full Text ORIGINAL ARTICLE OPEN ACCESS Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis Huiying Rao1,Xingxiang Yang2,Youwen Tan3,Qin Ning4,Daokun Yang5,Jiefei Wang6,Yongfeng Yang7,Sujun Zheng8,Dongliang Yang9,Jinlin Hou10,qing Xie11,Caiyan zhao12,Lunli zhang13,Xiaorong Mao14,Tong Sun15,Lang Bai16,Fuchun zhang17,Jinglan Jin18,Yingren zhao19,Maorong Wang20,Wen Xie21,Yingjie Ma22,Jun Quan23,Xuebing Yan24,Ping An25,Feng lin26,Jidong Jia27,Xiaoxuan Hu28,Zuojiong Gong29,Jie Wu30,Yongping Chen31,Zhansheng Jia32,Minghua lin33,Guiqiang Wang34,Yueyong Zhu35,Yingjun zhang*,36,Hongming Xie36,lin luo36,qingyun Ren36,Rui Huang1 and Lai Wei*,37 Author information Journal of Clinical and Translational Hepatology 2020;8(3):255-261DOI:10.14218/JCTH.2020.00031 Abstract Background and Aims:Emitasvir is a new type of hepatitis C virus(HCV)nonstructural protein 5A(NS5A)inhibitor,and the data of phase 2 trial has shown emitasvir-sofosbuvir to have good safety and *** conducted this phase 3 trial to further verify the efficacy and ***:We evaluated the antiviral activity and safety of a 12-week regimen of emitasvir phosphate(100 mg)combined with sofosbuvir(400 mg)once daily in non-cirrhotic patients with genotype 1 HCV *** primary endpoint was a sustained virological response at 12 weeks(SVR12)after the end of ***:Of the 362 patients enrolled in the trial,39.8%were male,99.2%had HCV genotype 1b,0.8%had genotype 1a and 79.8%were treatment-naï*** average age was 47.2 *** patients completed the treatment and *** 3 patients with genotype 1a achieved *** genotype 1b treatment-naïve patients experienced virologic *** rate of SVR12 was 99.7%(358/359),and SVR24 was 99.4%(357/359)in genotype ***,36.2%had resistance-associated substitutions(RASs)in NS5A and 98.3%had RASs in

关键词： Hepatitis C virus Genotype 1 Direct acting antivirals Emitasvir Sofosbuvir Combination treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomarkers of aging

引用

Science china(Life Sciences) 2023年第5期66卷 893-1066页

作者： Aging Biomarker Consortium Hainan Bao Jiani Cao Mengting Chen Min Chen Wei Chen Xiao Chen Yanhao Chen Yu Chen Yutian Chen Zhiyang Chen Jagadish K Chhetri Yingjie ding Junlin Feng Jun Guo Mengmeng Guo Chuting He Yujuan Jia Haiping Jiang Ying Jing dingfeng Li Jiaming Li Jingyi Li Qinhao liang Rui liang Feng Liu Xiaoqian Liu Zuojun Liu Oscar Junhong luo Jianwei Lv Jingyi Ma kehang Mao Jiawei Nie Xinhua Qiao Xinpei Sun Xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang Yuhan Wang Rimo Wu Kai Xia Fu-Hui Xiao lingyan Xu Yingying Xu haoteng Yan liang Yang Ruici Yang Yuanxin Yang Yilin Ying Le zhang Weiwei zhang Wenwan zhang Xing zhang Zhuo zhang Min Zhou Rui Zhou qingchen Zhu Zhengmao Zhu Feng Cao Zhongwei Cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen ding Qiurong ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju qing-Peng Kong Ji Li Jian Li Xin Li Baohua Liu Feng Liu lin Liu Qiang Liu Qiang Liu Xingguo Liu Yong Liu Xianghang luo Shuai Ma Xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi song Zhou songyang Yi Eve Sun Yu Sun Mei Tian Shusen Wang Si Wang Xia Wang Xiaoning Wang Yan-Jiang Wang Yunfang Wang Catherine CL Wong Andy Peng Xiang Yichuan Xiao Zhengwei Xie Daichao Xu Jing Ye Rui Yue Cuntai zhang Hongbo zhang liang zhang Weiqi zhang Yong zhang Yun-Wu zhang Zhuohua zhang Tongbiao zhao Yuzheng zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui Liu Aging Biomarker Consortium(ABC) Beijing 100101China CAS key Laboratory of Genomic and Precision Medicine Beijing Institute of GenomicsChinese Academy of Sciences and China National Center for BioinformationBeijing 100101China State key Laboratory of Stem Cell and Reproductive Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China department of dermatology Xiangya HospitalCentral South UniversityChangsha 410008China Hunan key Laboratory of Aging Biology Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research Center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangsha 410008China Clinic Center of Human Gene Research Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Hubei Clinical Research Center of Metabolic and Cardiovascular Disease Huazhong University of Science and TechnologyWuhan 430022China Hubei key Laboratory of Metabolic Abnormalities and Vascular Aging Huazhong University of Science and TechnologyWuhan 430022China Stem Cell Translational Research Center Tongji HospitalTongji University School of MedicineShanghai 200065China department of Nuclear Medicine Daping HospitalThird Military Medical UniversityChongqing 400042China CAS key Laboratory of Nutrition Metabolism and Food SafetyShanghai Institute of Nutrition and HealthUniversity of Chinese Academy of SciencesChinese Academy of SciencesShanghai 200031China Shanghai key Laboratory of Maternal Fetal Medicine Clinical and Translational Research Center of Shanghai First Maternity and Infant HospitalFrontier Science Center for Stem Cell ResearchShanghai Key Laboratory of Signaling and Disease ResearchSchool of Life Sciences and TechnologyTongji UniversityShanghai 200092China The department of Endovascular surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China key Laboratory of Regenerative Medicine of Ministry of Education Institute of Ageing and Regenerative MedicineJ

Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological *** a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly *** immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this ***,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory *** fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.

关键词： aging senescence biomarker clock

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical epidemiological survey of gallbladder carcinoma in northwestern china, 2009-2013: 2379 cases in 17 centers

引用

Chronic Diseases and Translational Medicine 2017年第1期3卷 -页

作者： hao-Xin Shen Hu-Wei song Xin-Jian Xu Zuo-Yi Jiao Zhen-Yu Ti zhao-Yu Li Bin Ren Chen Chen Li Ma Ya-ling zhao Guan-Jun zhang Jian-Cang Ma Xi-lin geng Xiao-Di zhang Jing-Sen Shi lin Wang Zhi-Min geng department of hepatobiliary surgery First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 China department of general surgery First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China department of hepatobiliary surgery Second Affiliated Hospital of Lanzhou University Lanzhou Gansu 730030 China department of hepatobiliary surgery Lanzhou General Hospital of Lanzhou Military Region Lanzhou Gansu 730050 China department of hepatobiliary surgery General Hospital of Ningxia Medical University Yinchuan Ningxia 750004 China department of hepatobiliary surgery Affiliated Hospital of Qinghai University Xining Qinghai 810001 China Faculty of Public Health School of Medicine Xi'an Jiaotong University Xi'an Shaanxi 710061 China department of Pathology First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 China department of general surgery Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710004 China department of hepatobiliary surgery Shaanxi People's Hospital Xi'an Shaanxi 710068 China department of hepatobiliary surgery Shaanxi Nuclear Industry 215 Hospital Xianyang Shaanxi 712000 China

Objective: To analyze the clinical epidemiological characteristics of patients with gallbladder carcinoma recruited from 17 hospitals in five northwestern provinces of china (Shaanxi Province, Gansu Province, qinghai Province, Ningxia Hui Autonomous Region, and Xinjiang Uygur Autonomous Region) from 2009 to 2013, and to summarize the clinical diagnosis and treatment data of gallbladder carcinoma. Methods: Clinical information of 2379 patients with gallbladder carcinoma from 17 hospitals in five northwestern provinces of china was retrospectively collected and analyzed using the 'Questionnaire for Gallbladder Carcinoma Patients in Northwestern Area of china.' All information was verified with EpiData software and analyzed with SPSS 13.0 software. Results: (1) Gallbladder carcinoma accounted for 2.7% (2379/86,609) of all biliary tract diseases during the study period, which was significantly higher than that from 1986 to 1998 (P der carcinoma was more prone to occur in elderly women. The male:female incidence ratio was 1.0:2.1, the average age of onset of disease was 63.7 ± 11.3 years, and the incidence was higher in farmers than in other occupational groups. (3) A total of 57.2% (1360/2379) of patients with gallbladder carcinoma also had gallstones. (4) Abdominal pain (1796/2379, 75.5%) and jaundice (727/2379, 30.6%) were the most common clinical manifestations, 81.2% (1527/1881) were positive in those receiving B ultrasound examinations and 90.7% (1567/1727) were positive in those undergoing computed tomography, and 64.5% (1124/1742) of patients with gallbladder carcinoma were positive for carbohydrate antigen (CA) 19-9. (5) The pathological type of gallbladder carcinoma was mainly moderately and poorly differentiated adenocarcinoma with a high degree of malignancy. At admission, 55.1% (1091/1981) of patients had stage Ⅳ cancer among patients with TNM staging information; 55.9% (1331/2379) had lymphatic metastasis, 29.7% (706/2379) had bile duc

关键词： Gallbladder carcinoma Epidemiology Incidence Risk factor Northwestern china

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Increased circulating level of interleukin-6 and CD8+T cell exhaustion are associated with progression of COVID-19

引用

Infectious Diseases of Poverty 2020年第6期9卷 42-50页

作者： Peng-Hui Yang Yi-Bo ding Zhe Xu Rui Pu Ping U Jin Yan Ji-luo Liu Fan-Ping Meng Lei Huang Lei Shi Tian-Jun Jiang En-Qiang Qin Min zhao Da-Wei zhang Peng zhao ling-Xiang Yu zhao-Hai Wang Zhi-Xian Hong zhao-Hui Xiao qing Xi de-Xi zhao Peng Yu Cai-Zhong Zhu Zhu Chen Shao-geng zhang Jun-Sheng Ji Fu-Sheng Wang Guang-Wen Cao department of hepatobiliary The Fifth Medical Center of PLA General HospitalNational Clinical Research Center for Infectious DiseasesBeijing100039China Treatment and Research Center for Infectious Diseases The Fifth Medical Center of PLA General HospitalNational Clinical Research Center for Infectious DiseasesBeijing100039China department of Epidemiology Second Military Medical UniversityShanghai200433China

Background: Coronavirus disease 2019(COVID-19)is *** is critical to identify COVID-19 patients who are most likely to develop a severe *** study was designed to determine the clinical and epidemiological features of COVID-19 patients associated with the development of pneumonia and factors associated with disease ***:: Seventy consecutive patients with etiologically confirmed COVID-19 admitted to pla general hospital in Beijing,china from december 27,2019 to March 12,2020 were enrolled in this study and followed-up to March 16,*** in clinical and laboratory findings between COVID-19 patients with pneumonia and those without were determined by theχ2 test or the Fisher exact test(categorical variables)and independent group t test or Mann–Whitney U test(continuous variables).The Cox proportional hazard model and generalized Estimating Equations were applied to evaluate factors that predicted the progression of ***: The mean incubation was 8.67(95%confidence interval,6.78–10.56)*** duration from the first test severe acute respiratory syndrome coronavirus 2-positive to conversion was 11.38(9.86–12.90)*** to pneumonia-free patients,pneumonia patients were 16.5 years older and had higher frequencies of having hypertension,fever,and cough and higher circulating levels of neutrophil proportion,interleukin-6,low count(deteriorated during *** regression analysis indicated that older age and higher serum levels of interleukin-6,C-reactive protein,procalcitonin,and lactate at admission significantly predicted the progression of *** hospitalization,circulating counts of T lymphocytes,CD4+T cells,and CD8+T cells were lower,whereas neutrophil proportion,neutrophil/lymphocyte ratio,and the circulating levels of interleukin-6,C-reactive protein,and procalcitonin were higher,in pneumonia patients than in pneumo

关键词： COVID-19 Progression Interleukin-6 CD8+T cell exhaustion Prospective case series

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：